Skip to content
NKCELLThe NK guide

Research & evidence

How Japan’s Regenerative Medicine Records Are Organised

A plain-English guide to Japan’s three separate regenerative-medicine records—research plans, treatment provision plans and PMDA product approvals—and why a single listing cannot answer all three questions.

Japan does not keep one master regenerative-medicine list that answers “is this treatment approved?” It keeps separate records for research plans, non-research treatment provision plans and product approvals. A concrete example: an entry in the health ministry’s e-再生医療 list of published treatment provision plans is a plan record. The plan list documents provision plans. PMDA maintains a separate product review route, and clinical benefit requires outcome evidence. To check a product, use the PMDA route; to check a study, use the research route; to understand a treatment plan, use the provision-plan record.

Three record routes, three different questions

Think of the system as three shelves rather than one approval ladder. That is an interpretation of how the records line up, not a claim that one shelf is better than another.

Swipe or scroll to read the full table →

Record route Who publishes it What it records What it does not establish
Research plan registration (jRCT) MHLW says research regenerative-medicine plans go through jRCT That a research plan has been submitted through the research-registry route A trial result, a product approval or a patient benefit
Non-research treatment provision plan (e-再生医療) MHLW e-再生医療 publishes a list of notified treatment provision plans A plan for providing non-research regenerative medical care, with MHLW’s risk classes I, II and III Product approval or clinical benefit
Regenerative medical product approval (PMDA) PMDA’s review-services records Product-specific review and approval information for regenerative medical products That a treatment provision plan is a product approval; that a different product or indication is covered

The table is the map. The rest of the record is about the boundaries between the rows.

Why a provision plan is not a product approval

Under the 2025 revised Act handling notice, a provision plan goes through the opinion of the corresponding certified committee and is submitted to the government. That sequence is a regulatory step in the plan route. A committee opinion and government submission tell the reader how the plan moved through that process. Clinical outcomes and product approval require separate records. This is the single most useful distinction when reading Japanese regenerative-medicine records.

What the e-再生医療 list can and cannot tell you

MHLW’s e-再生医療 portal is the non-research route. Its public page publishes a list of treatment provision plans. The list is searchable, and its index includes entries labelled NK. That label is a pointer to a plan record, not a statement that a particular clinic has a PMDA-approved product, that the plan is current, or that the treatment has a patient benefit. A practical inference from the list’s structure is that it works as a plan index, not as a live approval-status page. If you need to know about a product, the plan list alone cannot answer that question.

Where PMDA fits, and why the product route is separate

PMDA is the Japanese regulator whose English review-services page covers regenerative medical products. MHLW’s provision-plan route and PMDA’s product route are different frameworks. That means a provision-plan record and a PMDA product record are not interchangeable. A PMDA record should be read for the product and indication it covers; it is not a general endorsement of every regenerative treatment at a site, and it does not turn a research plan into a result. The separation matters because one route asks how care is provided under the regenerative-medicine law, while the product route asks whether a specific regenerative medical product has been reviewed as a product.

A short reading guide for search results

Use the record type to frame the question:

  • If the result is a jRCT research entry, ask what study it describes and what phase it is in. A registration is not a result, and a trial design is not a patient benefit.
  • If the result is an e-再生医療 plan entry, ask whether it is a treatment plan, and note its risk class I, II or III. Do not convert the plan into a product approval or an efficacy claim.
  • If the result is a PMDA product record, keep the product, indication and country in view. Do not carry that approval over to a different product or to a clinic’s other activities.

A single search for “regenerative medicine Japan” can surface all three. They are not competing versions of one status; they answer different questions.

General information about public records, not medical advice or a recommendation of any treatment.

Sources and further reading

Keep reading

Follow the next question.

Research & evidence